CheckMate 017

Background

Phase III, open-label RCT (CheckMate 017). N=272 with previously treated (≥1 prior platinum regimen) advanced squamous NSCLC, ECOG PS 0–1. No PD-L1 selection. First phase III trial demonstrating OS benefit of PD-1 inhibition in squamous NSCLC 2L.

Interventions and follow up

Arm A: Nivolumab 3 mg/kg IV q2wk until progression or toxicity (N=135)
Arm B: Docetaxel 75 mg/m² IV q3wk (N=137)
Primary endpoint: Overall survival
mFollow up: 11 months

Results

OS: 9.2 vs 6.0 mo, HR 0.59 (95% CI 0.44–0.79), P<.001
1-yr OS: 42% vs 24%
PFS: 3.5 vs 2.8 mo, HR 0.62 (0.47–0.81), P<.001
ORR: 20% vs 9%
PD-L1: no correlation between PD-L1 expression and OS benefit in squamous NSCLC

Adverse events

Overall (grade ≥3): 7% (nivolumab) vs 24% (docetaxel)
Endocrine: hypothyroidism 10% (all grades)
Pulmonary: pneumonitis 3% (all grades)
Hepatic: hepatitis <2%

Conclusions

Nivolumab significantly improved OS vs docetaxel in previously treated squamous NSCLC (HR 0.59), with markedly lower toxicity. PD-L1 expression did not predict benefit in squamous histology, making nivolumab an all-comer 2L option regardless of biomarker status.

Key Limitations

Open-label design. Short follow-up at primary analysis. No OS subgroup benefit by PD-L1 limits biomarker-guided selection. Docetaxel monotherapy comparator may underestimate the control arm (ramucirumab+docetaxel [REVEL] also standard). Does not address EGFR/ALK alterations. Now largely superseded by 1L IO + chemo in most patients.

Clinical Context

CheckMate 017 and 057 together established nivolumab as the first IO approved for 2L NSCLC (FDA 2015), transforming the post-platinum landscape. Alongside OAK (atezolizumab) and KEYNOTE-010 (pembrolizumab), defined modern 2L IO standards. 2L IO remains relevant for IO-naive patients. ESMO-MCBS 5.

References